Testing a desensitization method during chemotherapy for gynecologic cancers
Tests immune tolerance induction during early chemotherapy in people with gynecologic cancer.
Plain-language title generated from the registry record
Registry title: Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Seoul National University HospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University Hospital
- Trial code
- NCT06977594
- Record updated
- 7 October 2026
- Original description
The goal of this clinical trial is to evaluate the efficacy of proactive immune tolerance induction of chemotherapy (paclitaxel and carboplatin) for patients with gynecologic cancer.Read full original descriptionShow less
A Randomized, Placebo-controlled, Parallel-group, Open-label Trial to Evaluate the Efficacy of Proactive Immune Tolerance Induction to Paclitaxel and Carboplatin in Patients With Gynecologic Cancer
The goal of this clinical trial is to evaluate the efficacy of proactive immune tolerance induction of chemotherapy (paclitaxel and carboplatin) for patients with gynecologic cancer.
The main questions it aims to answer are:
- Does immune tolerance induction during the first three cycles of chemotherapy reduce the incidence of hypersensitivity reactions in the remaining cycles?
Participants will:
* Undergo immune tolerance induction or standard treatment during the first three cycles of chemotherapy as randomized, after which all participants will continue the remaining cycles with standard treatment. * Receive a reduced dose of dexamethasone premedication if assigned to the experimental group, depending on the specific protocol of each clinical trial.
Inclusion: Patients receiving paclitaxel and carboplatin chemotherapy for gynecologic malignancies; Patients with no prior history of hypersensitivity reactions to paclitaxel or carboplatin; Patients who are able to read and voluntarily provide written informed consent; Aged 19 years or older.
Exclusion: Patients who do not wish to participate in this study voluntarily; Patients who, in the opinion of the investigator, are unsuitable for participation in this clinical trial.